Abstract
Minimal residual disease (MRD) is an independent predictor of relapse risk for childhood acute lymphoblastic leukemia(ALL). The aim of study to investigate impact MRD by real-time quantitative polymerase chain reaction before (day –21) andat +30 ± 10, +60 ± 10, +100 ± 10, +180 ± 10, +365 ± 10 days after hematopoietic stem cell transplantation (HSCT), and PCR-chimerismon transplant outcomes children with ALL. The study was approved by the Independent Ethics Committee and the Scientific Councilof the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (Republic of Belarus). Fifty one patientswith ALL underwent allogeneic transplantation in remission (period 12.2010–12.2017, median follow-up 2,8 years). 3-years eventfreesurvival (EFS) and cumulative incidence of relapse (CIR) were 71.6 ± 17.1% and 14.3 ± 14.3% respectively for patients (n = 7)with pre-transplant MRD < 10-4 and 0% (n = 4, p = 0.0046) and 50.0 ± 29.2% (p = 0.3111) respectively for MRD ≥ 10-4. After HSCT(n = 29) 3-years EFS and CIR were 22.2 ± 13.9% and 66.7 ± 18.1% respectively for recipients (n = 9) with MRD ≥ 10-4 at leastin one analyzed point. In comparison, patients with MRD < 10-4 at all points (n = 20) had EFS and CIR 70.0 ± 10.2% (p = 0.0172)(HR = 12.3; 95% CI: 2.33–64.87; p = 0.0031), and 5.0±5.0% (p = 0.0004) (HR = 50.7; 2.5–97.5% CI: 1.60–1608.56; p = 0.0260)respectively. Patients with mixed chimerism at least in one analyzed point since day +30 to +365 hadn't significant differences OS,EFS, CIR but were worse (57.1%, 40.0% and 50.0% respectively) in comparison full chimerism patients (79.5% (p = 0.248), 71.4%(p = 0.072) and 20.0% (p = 0.070) respectively). MRD is significant predictor of relapse risk for childhood ALL at time of HSCT.MRD < 10-4 patients have significantly better EFS and CIR in comparison MRD ≥ 10-4 patients before and after HSCT.
Highlights
Поступила 02.12.2019 Принята к печати 28.01.2020 трансплантации гемопоэтических стволовых клеток у детей, подростков и молодых пациентов с острым лимфобластным лейкозом
The study was approved by the Independent Ethics Committee and the Scientific Council of the Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (Republic of Belarus)
Период рецидива до трансплантацией гемопоэтических стволовых клеток (ТГСК): Time relapse before hematopoietic stem cell transplantation (HSCT): поздний late ранний и очень ранний early and very early
Summary
Влияние значения минимальной остаточной болезни на риск развития рецидива при аллогенной. ГУ «Республиканский научно-практический центр детской онкологии, гематологии и иммунологии», Республика Беларусь. Цель работы: оценить влияние МОБ, отслеживаемой по реаранжировкам генов IgH, IgK, TCRB, TCRG, TCRD перед аллогенной трансплантацией гемопоэтических стволовых клеток (алло-ТГСК) и после нее, химеризма, определенного методом полимеразной цепной реакции (ПЦР), после ТГСК на частоту развития рецидива, общую (ОВ) и бессобытийную (БСВ) выживаемость у пациентов с ОЛЛ. Перед ТГСК 3-летняя БСВ и кумулятивная частота рецидива (КЧР) составили 71,6 ± 17,1% и 14,3 ± 14,3% соответственно у пациентов (n = 7) со значением МОБ < 10–4 и 0% (p = 0,0046) и 50,0 ± 29,2% (p = 0,3111) соответственно у больных (n = 4) при МОБ ≥ 10–4. МОБ является значимым фактором риска развития рецидива и фактором, оказывающим влияние на выживаемость пациентов с ОЛЛ после алло-ТГСК.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
